Bernstein Upgrades Edwards Lifesciences(EW.US) to Hold Rating

联博集团上调爱德华生命科学(EW.US)至持有评级

moomoo资讯 · 2024/10/28 19:35 · 评级/大行评级

Bernstein analyst Lee Hambright upgrades $Edwards Lifesciences (EW.US)$ to a hold rating.

According to TipRanks data, the analyst has a success rate of 70.0% and a total average return of 11.9% over the past year.

AnalystRecentRatingAutoNews_205224_20241028_17ff9ad0581315f5a07f0e6c4b5e0a980c27e93d_1730115090125100_mm_en

Furthermore, according to the comprehensive report, the opinions of $Edwards Lifesciences (EW.US)$'s main analysts recently are as follows:

Edwards Lifesciences experienced a strong performance in terms of sales and earnings, and the forward-looking guidance for Q4, along with future projections up to 2025, are anticipated to sustain the stock's upward trajectory.
The expectation is that it will require several more quarters for Edwards Lifesciences to demonstrate to investors that the lowest point has been reached for its TAVR franchise following the Q3 report.
Expectations were moderate prior to the quarterly results, and the commentary for the third quarter, fourth quarter, and future fiscal year did not strongly suggest that risks had been fully accounted for. Although the deceleration in fourth quarter Transcatheter Aortic Valve Replacement (TAVR) trends may be due to some one-time factors, it remains challenging to counter the possibility that TAVR growth may continue to slow down in the coming fiscal year.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

联博集团分析师Lee Hambright上调$爱德华生命科学 (EW.US)$至持有评级。

根据TipRanks数据显示，该分析师近一年总胜率为70.0%，总平均回报率为11.9%。

AnalystRecentRatingAutoNews_205224_20241028_17ff9ad0581315f5a07f0e6c4b5e0a980c27e93d_1730115090125100_mm_sc

此外，综合报道，$爱德华生命科学 (EW.US)$近期主要分析师观点如下：

爱德华生命科学的销售和收益表现强劲，第四季度的前瞻指引以及未来到2025年的预测，预计将支撑股票的上升轨迹。
预期需要几个季度，爱德华生命科学向投资者证明其TAVR业务在Q3报告后已达到最低点。
在季度业绩公布前，市场对爱德华生命科学的预期较为温和，第三季度、第四季度和未来财政年度的评论并未明显暗示风险已充分考虑。尽管第四季度经皮主动脉瓣置换（TAVR）趋势的减速可能是由于一些一次性因素所致，但仍然难以排除TAVR增长在未来财政年度可能继续放缓的可能性。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Bernstein Upgrades Edwards Lifesciences(EW.US) to Hold Rating

Bernstein Upgrades Edwards Lifesciences(EW.US) to Hold Rating

风险及免责提示

声明